Market Place
Sourcing Support
ImCheck Receives FDA Fast Track For ICT01 In AML
18 Sep 2024 //
GLOBENEWSWIRE
Delta-Fly Initiates DFP-10917 Phase I/II Combo-study In AML
10 Sep 2024 //
BUSINESSWIRE
SELLAS Life Sciences Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Aptose Reports Results for the Second Quarter 2024
08 Aug 2024 //
GLOBENEWSWIRE
AstraZeneca trumpets new Calquence combos in chronic lymphocytic leukaemia
30 Jul 2024 //
PRESS RELEASE
BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data
14 Jun 2024 //
BUSINESSWIRE
IMBRUVICA Plus Venetoclax Shows Sustained Benefit In CLL
14 Jun 2024 //
GLOBENEWSWIRE
Delta-Fly Notice to Conduct the Ph I/II of DFP-10917 combined with Venetoclax
08 Apr 2024 //
BUSINESSWIRE
MEI Update from Study Evaluating Voruciclib with Venetoclax in Patients with AML
26 Mar 2024 //
BUSINESSWIRE
Delta-Fly: FDA submission of the protocol of the Phase I/II study of DFP-10917
11 Mar 2024 //
BUSINESSWIRE
Ryvu Announces Dosing of the First Patient in RIVER-81 Phase II Study of RVU120
31 Jan 2024 //
PR NEWSWIRE
Vincerx Announces Compelling Efficacy of Enitociclib with Venetoclax
07 Jan 2024 //
GLOBENEWSWIRE
An Imbruvica combo regimen could have a new future in MCL
13 Dec 2023 //
FIERCE PHARMA
ImmunoGen Presents Findings from Phase 1b/2 Study of Pivekimab Sunirine at ASH
10 Dec 2023 //
BUSINESSWIRE
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
06 Dec 2023 //
BUSINESSWIRE
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax
29 Sep 2023 //
PR NEWSWIRE
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter
23 Jun 2023 //
ONCOLIVE
Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD
22 Jun 2023 //
ONCLIVE
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
22 Jun 2023 //
PRESS RELAESE
Ibrutinib, Obinutuzumab, Venetoclax Triplet Elicits Clinical Benefit in MCL
19 Jun 2023 //
ONCLIVE
AbbVie`s VENCLYXTO/VENCLEXTA Continues to Show Sustained PFS in CLL
09 Jun 2023 //
PR NEWSWIRE
MEI Pharma Announces Update of PI Study Evaluating CDK9 Inhibitor Voruciclib
23 May 2023 //
BUSINESSWIRE
Ph 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done
15 May 2023 //
BUSINESSWIRE
NICE signs off on AbbVie, J&J`s Imbruvica-Venclyxta combo in CLL
22 Apr 2023 //
FIERCE PHARMA
NICE gives green light to ibrutinib plus venetoclax for lymphocytic leukaemia
21 Apr 2023 //
PHARMIWEB
FDA puts Curis` leukemia trial on partial hold after patient death
04 Apr 2023 //
FIERCE BIOTECH
100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436
12 Dec 2022 //
ACCESSWIRE
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept
12 Dec 2022 //
GLOBENEWSWIRE
Kymera Presents Preclinical Data Demonstrating Activity of KT-253 at ASH
11 Dec 2022 //
GLOBENEWSWIRE
Results from PIII Study of Fixed-Duration Treatment with IMBRUVICA show Efficacy
10 Dec 2022 //
PRNEWSWIRE
ImmunoGen Presents Findings from Cohorts in Phase 1b/2 of Pivekimab Sunirine
10 Dec 2022 //
BUSINESSWIRE
Imago Announces 1st Participant Dosed Ph1 Study of Bomedemstat Combo Venetoclax
30 Nov 2022 //
GLOBENEWSWIRE
Biosight Launches a Phase 1/2 Trial of Aspacytarabine with Venetoclax
22 Nov 2022 //
PRNEWSWIRE
AbbVie calls off PI trial for I-Mab’s CD47 after Zai Lab shelves program
17 Aug 2022 //
ENDPTS
SMC accepts chemotherapy-free VENCLYXTO for leukaemia treatment
10 May 2022 //
PHARMAFILE
Cyclacel Pharma to Publish Confirming Fadraciclib Suppresses MCL1 and CLL
12 Apr 2022 //
GLOBENEWSWIRE
Zosano Pharma Announces Reverse Stock Split Effective Today
11 Apr 2022 //
GLOBENEWSWIRE
NICE recommend venetoclax and azacytidine for patients with blood cancer
16 Dec 2021 //
PHARMATIMES
Venetoclax combination therapies found effective against challenging subtypes
13 Dec 2021 //
PRESS RELEASE
Actinium Evaluates Primary Endpoint of Pivotal Phase 3 SIERRA Trial
13 Dec 2021 //
PRNEWSWIRE
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA in CLL
12 Dec 2021 //
BUSINESSWIRE
ImmunoGen: Initial Findings From Phase 1b/2 Study of IMGN632+Vidaza & Venclexta
12 Dec 2021 //
BUSINESSWIRE
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt
09 Dec 2021 //
GLOBENEWSWIRE
ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza®
04 Nov 2021 //
BUSINESSWIRE
FDA slaps clinical hold on AstraZeneca cancer drug
21 Oct 2021 //
FIERCEBIOTECH
First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab
18 Jun 2021 //
CANCERTHERAPYADVISOR
IMBRUVICA + VENCLEXTA®/VENCLYXTO Proves Superior to Chlorambucil + Obinutuzumab
14 Jun 2021 //
PRNEWSWIRE
IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results
14 Jun 2021 //
PRESS RELEASE
First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab
12 Jun 2021 //
PRNEWSWIRE
MHRA approves Venclyxto for newly diagnosed AML
11 Jun 2021 //
PHARMATIMES
Genentech Announces Data at EHA2021
11 Jun 2021 //
BUSINESSWIRE
Genentech Announces Data at EHA2021
11 Jun 2021 //
BUSINESSWIRE
Genentech Reports Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations
10 Jun 2021 //
BUSINESSWIRE
MHRA approves venetoclax as acute myeloid leukemia treatment
08 Jun 2021 //
PHARMAFILE
MHRA approves venetoclax as acute myeloid leukemia treatment
08 Jun 2021 //
PHARMAFILE
AbbVie, J&J`s Imbruvica racks up data for Venclexta combo nod
18 May 2021 //
FIERCEPHARMA
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax)
22 Apr 2021 //
PRNEWSWIRE
Health Canada Approves VENCLEXTA® (venetoclax) in combination with azacitidine
15 Dec 2020 //
NEWSWIRE
Venetoclax Plus Navitoclax Shows Promise for Paediatric Acute Lymphoblastic
11 Dec 2020 //
FIRSTWORDPHARMA
